Legend to the supplementary figures

Fig. S1 *Expression pattern of EBV latent genes in BL cell lines and LCLs.* 100 μg of cell lysate from each cell lines were resolved on a 12% SDS-PAGE, transferred to membranes and hybridized with the following antibodies: EBNA1 (OT1X CytoBarr, 1:1000); EBNA2 (PE2), and EBNA3C (E3cA10) kindly provided by Dr. M. Rowe, were used 1:2000); LMP1 (S12 Pharmingen, 1:7500); LMP2A (14B7 Santa Cruz, 1:200). Specific signals were visualized by ECL.

Fig. S2 *Supershift assay* . The cell extracts from control cells and cells treated for three hours with RV, were incubated with anti-p65 or anti-p50 antibodies and analyzed by EMSA. Lane 1, without cell extract; Lane 2 and 6, kB probe alone; Lane 3 and 7, with p65 antibody; Lane 4 and 8 with p50 antibody; Lane 5, unlabeled probe.

Fig. S3 *AP1 activity in resveratrol-treated BL cells*. (a) At the indicated times (hours), whole-cell extracts were incubated with a consensus AP1 binding site oligonucleotide to evaluate AP1 activity by EMSA (see Methods).

Fig. S4 *Resveratrol-induced inhibition of LCLs proliferation*. Cells were incubated with RV at the concentrations indicated. After 24, 48 and 72 hours, cell counts were assessed by trypan blue staining and the values expressed as percentage of control cells treated with the diluent. Each point represents the mean ± SD of three similar experiments.